Recall archive / FDA company announcement
Hospira: 4.2% Sodium Bicarbonate Injection, USP, 1% Lidocaine HCl Injection, USP, and 2% Lidocaine HCl Injection, USP — FDA announcement Oct 2, 2023
Reported terminated
A company announcement posted by FDA. The listing date can differ from the original announcement date. The absence of a termination marker does not prove the recall is currently ongoing.
Source date Oct 2, 2023. Retrieved Oct 1, 2026. Last updated Oct 1, 2026.
Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.
What the record says
- Product
- 4.2% Sodium Bicarbonate Injection, USP, 1% Lidocaine HCl Injection, USP, and 2% Lidocaine HCl Injection, USP
- Reason
- Potential Presence of Glass Particulates
- Classification
- Not supplied
- Recalling firm
- Hospira, Inc.
- Quantity
- Not supplied
- Agency-reported status
- Terminated in FDA listing
- Source record identifier
- b9ce6d938645f011
Lot and product identifiers
| Label field | Details supplied by the agency |
|---|---|
| Lot, code or applicability | The NDC, Lot Number, Expiration Date, and Configuration details for the impacted products are indicated below. The products were distributed nationwide to wholesalers/hospitals/institutions in the United States and Puerto Rico from October 13, 2022 through October 26, 2022.; Wholesalers, hospitals, institutions, and doctors with an existing inventory of a lot which is being recalled should discontinue use, stop distribution and quarantine the product immediately. If you have further distributed the recalled product, please notify your accounts and/or any additional locations which may have received the recalled product. Hospitals/Institutions should inform Healthcare Professionals in your organization of this recall. For additional assistance, call Sedgwick Inc. at 1-800-805-3093 between the hours of 8 a.m. to 5 p.m. ET, Monday through Friday.; Product | NDC | Lot Number | Expiration Date | Presentation | Configuration/ Count; 4.2% Sodium Bicarbonate Injection, USP Glass ABBOJECT® Syringe | Carton 0409-5534-24 Case 0409-5534-14 | GJ5007 | 1AUG2024 | 5 mEq/10mL, (0.5 mEq/mL) | 1 vial and injector/ carton 10 cartons/ bundle Case pack 5 X 10- 10mL; 1% Lidocaine HCl Injection, USP LIFESHIELD® Glass ABBOJECT® Syringe | Carton 0409-4904-11 Case 0409-4904-34 | 42290DK | 1JUN2024 | 50 mg/5mL (10 mg/mL) | 1 vial and injector/ carton 10 cartons/ bundle Case pack 5 X 10- 5mL; 2% Lidocaine HCl Injection, USP LIFESHIELD® Glass ABBOJECT® Syringe | Carton 0409-4903-11 Case 0409-4903-34 | GH6567 | 1JUL2024 | 100 mg/5mL (20 mg/mL) | 1 vial and injector/ carton 10 cartons/ bundle Case pack 5 X 10- 5mL; Contact Center | Contact Information | Area of Support; Pfizer Medical Information | 1-800-438-1985, option 3 (8am to 7pm ET Monday through Friday) www.pfizermedinfo.com | For medical questions regarding the product; Pfizer Drug Safety | 1-800-438-1985, option 1 (24 hours a day; 7 days a week) | To report adverse events and product complaints |
Match all identifying details in the current notice. A brand name alone is not enough.
Product tables from the announcement
These identifying details come from the company announcement posted by FDA. Check the current notice for revisions.
| Product | NDC | Lot Number | Expiration Date | Presentation | Configuration/ Count |
|---|---|---|---|---|---|
| 4.2% Sodium Bicarbonate Injection, USP Glass ABBOJECT® Syringe | Carton 0409-5534-24 Case 0409-5534-14 | GJ5007 | 1AUG2024 | 5 mEq/10mL, (0.5 mEq/mL) | 1 vial and injector/ carton 10 cartons/ bundle Case pack 5 X 10- 10mL |
| 1% Lidocaine HCl Injection, USP LIFESHIELD® Glass ABBOJECT® Syringe | Carton 0409-4904-11 Case 0409-4904-34 | 42290DK | 1JUN2024 | 50 mg/5mL (10 mg/mL) | 1 vial and injector/ carton 10 cartons/ bundle Case pack 5 X 10- 5mL |
| 2% Lidocaine HCl Injection, USP LIFESHIELD® Glass ABBOJECT® Syringe | Carton 0409-4903-11 Case 0409-4903-34 | GH6567 | 1JUL2024 | 100 mg/5mL (20 mg/mL) | 1 vial and injector/ carton 10 cartons/ bundle Case pack 5 X 10- 5mL |
| Contact Center | Contact Information | Area of Support |
|---|---|---|
| Pfizer Medical Information | 1-800-438-1985, option 3 (8am to 7pm ET Monday through Friday) www.pfizermedinfo.com | For medical questions regarding the product |
| Pfizer Drug Safety | 1-800-438-1985, option 1 (24 hours a day; 7 days a week) | To report adverse events and product complaints |
Announcement retrieved Oct 1, 2026. Official announcement.
Distribution
The NDC, Lot Number, Expiration Date, and Configuration details for the impacted products are indicated below. The products were distributed nationwide to wholesalers/hospitals/institutions in the United States and Puerto Rico from October 13, 2022 through October 26, 2022. Wholesalers, hospitals, institutions, and doctors with an existing inventory of a lot which is being recalled should discontinue use, stop distribution and quarantine the product immediately. If you have further distributed the recalled product, please notify your accounts and/or any additional locations which may have received the recalled product. Hospitals/Institutions should inform Healthcare Professionals in your organization of this recall. For additional assistance, call Sedgwick Inc. at 1-800-805-3093 between the hours of 8 a.m. to 5 p.m. ET, Monday through Friday.
States below are derived from the distribution text, including nationwide wording. They are not inferred from the firm's address.
- Alaska
- Alabama
- Arkansas
- Arizona
- California
- Colorado
- Connecticut
- Delaware
- Florida
- Georgia
- Hawaii
- Iowa
- Idaho
- Illinois
- Indiana
- Kansas
- Kentucky
- Louisiana
- Massachusetts
- Maryland
- Maine
- Michigan
- Minnesota
- Missouri
- Mississippi
- Montana
- North Carolina
- North Dakota
- Nebraska
- New Hampshire
- New Jersey
- New Mexico
- Nevada
- New York
- Ohio
- Oklahoma
- Oregon
- Pennsylvania
- Rhode Island
- South Carolina
- South Dakota
- Tennessee
- Texas
- Utah
- Virginia
- Vermont
- Washington
- Wisconsin
- West Virginia
- Wyoming
Dates in the source
- Fda listing date
- Oct 2, 2023
- Company announcement date
- Oct 2, 2023
FDA company pages use the listing date; enforcement records use initiation dates; CPSC uses recall date; NHTSA uses report-received date. These dates are not interchangeable.